Transaction DateRecipientSharesTypePriceValue
14th December 2020David R Guyer9,270Open or private sale$7.16$66,373.20
14th December 2020Keith Westby4,527Open or private sale$7.16$32,413.32
12th December 2020David R Guyer17,200Exercise of derivative$0.00
12th December 2020Glenn Sblendorio22,950Exercise of derivative$0.00
12th December 2020David Francis Carroll12,500Exercise of derivative$0.00
12th December 2020Keith Westby12,500Exercise of derivative$0.00
10th December 2020David R Guyer9,602Open or private sale$6.96$66,829.92
10th December 2020Keith Westby3,676Open or private sale$6.96$25,584.96
9th December 2020David Francis Carroll10,000Exercise of derivative$0.00
9th December 2020Keith Westby10,000Exercise of derivative$0.00
Iveric Bio
Iveric Bio logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

The company is developing novel therapeutics to treat diseases of the eye. The company is based in San Francisco and has offices in New York and London.

Ticker: OPHT
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1410939
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags